RJFSA
UBX

Raymond James Financial Services Advisors’s Unity Biotechnology UBX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,011
Closed -$47K – 3418
2021
Q2 		$47K Sell
1,011
-39
-4% -$1.88K ﹤0.01% 3217
2021
Q1 		$63K Buy
+1,050
New +$71.6K ﹤0.01% 3081

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Raymond James Financial Services Advisors's UBX Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 1,011 shares — an estimated $47K sold.

Raymond James Financial Services Advisors first reported a position in UBX in Q1 2021 and held it in 2 quarters. The position peaked at $63K in Q1 2021. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 1,011 Unity Biotechnology shares in Q3 2021, an estimated $47K.
  • Raymond James Financial Services Advisors first reported a position in Unity Biotechnology in Q1 2021 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Unity Biotechnology position peaked at $63K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.